Alnylam Pharmaceuticals (NASDAQ:ALNY) Rating Increased to Buy at StockNews.com

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) was upgraded by stock analysts at StockNews.com from a "hold" rating to a "buy" rating in a note issued to investors on Tuesday.

Other equities research analysts also recently issued research reports about the company. Redburn Atlantic assumed coverage on Alnylam Pharmaceuticals in a research report on Monday, March 31st. They set a "buy" rating and a $353.00 price objective on the stock. Chardan Capital restated a "buy" rating and set a $300.00 price target on shares of Alnylam Pharmaceuticals in a research note on Friday, March 21st. William Blair reiterated an "outperform" rating on shares of Alnylam Pharmaceuticals in a research report on Friday, March 21st. Scotiabank upped their target price on Alnylam Pharmaceuticals from $338.00 to $342.00 and gave the company a "sector outperform" rating in a research report on Monday, March 31st. Finally, Canaccord Genuity Group upped their price objective on Alnylam Pharmaceuticals from $385.00 to $390.00 and gave the stock a "buy" rating in a research report on Friday, March 21st. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and twenty-two have assigned a buy rating to the stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $315.58.

Alnylam Pharmaceuticals Trading Up 3.7 %

Shares of ALNY traded up $8.95 during mid-day trading on Tuesday, reaching $251.56. 835,531 shares of the company's stock traded hands, compared to its average volume of 879,273. The stock has a market cap of $32.72 billion, a P/E ratio of -115.93 and a beta of 0.30. The stock's 50-day moving average is $247.37 and its two-hundred day moving average is $255.84. Alnylam Pharmaceuticals has a 12 month low of $143.50 and a 12 month high of $304.39. The company has a debt-to-equity ratio of 15.27, a current ratio of 2.78 and a quick ratio of 2.71.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last announced its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.62) by ($0.03). Research analysts forecast that Alnylam Pharmaceuticals will post -1.7 earnings per share for the current fiscal year.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other news, CMO Pushkal Garg sold 52,592 shares of the company's stock in a transaction that occurred on Monday, January 27th. The shares were sold at an average price of $285.00, for a total value of $14,988,720.00. Following the transaction, the chief marketing officer now directly owns 11,989 shares in the company, valued at approximately $3,416,865. This represents a 81.44 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Yvonne Greenstreet sold 1,213 shares of the company's stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $255.17, for a total transaction of $309,521.21. Following the completion of the transaction, the chief executive officer now owns 81,526 shares in the company, valued at approximately $20,802,989.42. This represents a 1.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 59,984 shares of company stock worth $16,864,347 in the last ninety days. 1.20% of the stock is owned by insiders.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

Several large investors have recently made changes to their positions in the stock. Capital World Investors increased its stake in Alnylam Pharmaceuticals by 0.6% during the 4th quarter. Capital World Investors now owns 16,600,525 shares of the biopharmaceutical company's stock worth $3,906,284,000 after buying an additional 92,101 shares during the period. Vanguard Group Inc. increased its stake in Alnylam Pharmaceuticals by 0.8% during the 4th quarter. Vanguard Group Inc. now owns 12,733,399 shares of the biopharmaceutical company's stock worth $2,996,296,000 after buying an additional 98,303 shares during the period. Capital Research Global Investors increased its stake in Alnylam Pharmaceuticals by 32.9% during the 4th quarter. Capital Research Global Investors now owns 6,968,513 shares of the biopharmaceutical company's stock worth $1,639,767,000 after buying an additional 1,724,610 shares during the period. Regeneron Pharmaceuticals Inc. purchased a new stake in Alnylam Pharmaceuticals during the 4th quarter worth approximately $1,045,822,000. Finally, T. Rowe Price Investment Management Inc. increased its stake in Alnylam Pharmaceuticals by 39.7% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 4,384,449 shares of the biopharmaceutical company's stock worth $1,031,705,000 after buying an additional 1,245,195 shares during the period. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.